Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.
Follow MREO
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cost of Revenue |
— | — | 0.00 | — |
+8 more quarters Free account |
Gross Profit |
— | — | 0.00 | — | |
R&D Expenses |
1.81 | 4.75 | 4.19 | 4.27 | |
SG&A Expenses |
5.22 | 4.02 | 4.20 | 6.05 | |
Operating Income |
(7.03) | (8.77) | (8.09) | (10.31) | |
Non-operating Interest Expenses |
0.02 | 0.02 | 0.02 | 0.03 | |
Non-operating Income/Expense |
0.03 | 2.05 | 0.74 | 3.29 | |
| (7.00) | (6.72) | (7.35) | (7.02) | ||
Income after Tax |
(7.00) | (6.72) | (7.35) | (7.02) | |
Net Income Common |
(7.00) | (6.72) | (7.35) | (7.02) | |
EPS (Basic) |
(0.04) | (0.04) | (0.05) | (0.04) | |
EPS (Diluted) |
(0.04) | (0.04) | (0.05) | (0.04) | |
Shares (Basic, Weighted) |
160.71 | 160.36 | 159.42 | 159.99 | |
Shares (Diluted, Weighted) |
160.71 | 160.36 | 159.42 | 159.99 | |
Gross Margin |
— | — | 0.00% | — | |
EBIT Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBT margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBITDA |
(6.86) | (8.59) | (7.63) | (10.46) | |
EBIT |
(7.03) | (8.77) | (8.09) | (10.31) | |
Income from Continuous Operations |
(7.00) | (6.72) | (7.35) | (7.02) | |
Consolidated Net Income/Loss |
(7.00) | (6.72) | (7.35) | (7.02) | |
EPS (Basic, from Continuous Ops) |
(0.04) | (0.04) | (0.05) | (0.04) | |
EPS (Diluted, from Cont. Ops) |
(0.04) | (0.04) | (0.05) | (0.04) | |
EPS (Basic, Consolidated) |
(0.04) | (0.04) | (0.05) | (0.04) | |
EPS (Diluted, Consolidated) |
(0.04) | (0.04) | (0.05) | (0.04) | |
Shares (Diluted, Average) |
803.56 | 801.81 | 735.10 | 799.95 | |
EBITDA Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating Cash Flow Margin |
0.00% | 0.00% | 0.00% | 0.00% |